Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

DISEASE CHARACTERISTICS: * Diagnosis of breast cancer at high risk for recurrence, defined by one of the following: * Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy * May or may not have elevated CA 15-3 or CEA levels * Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels * Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart * For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart * Stage III and completed adjuvant therapy no more than 24 months ago * Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy * Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection * Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago * Stage IV that is stable on hormonal therapy * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 18 and over Sex: * Male or female Menopausal status: * Not specified Performance status: * Karnofsky 80-100% Life expectancy: * Not specified Hematopoietic: * Lymphocyte count at least 500/mm\^3 * WBC at least 3,000/mm\^3 Hepatic: * AST no greater than 1.5 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 1.5 times ULN Renal: * Creatinine no greater than 1.5 times ULN Cardiovascular: * No clinically significant New York Heart Association class III or IV cardiac disease Other: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No prior seafood allergy * No known prior immunodeficiency or autoimmune disease * No other active cancer except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 6 weeks since prior immunotherapy * No prior vaccine with any of the antigens in this study Chemotherapy: * See Disease Characteristics * At least 4 weeks since prior chemotherapy * No concurrent chemotherapy Endocrine therapy: * See Disease Characteristics Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * See Disease Characteristics * At least 4 weeks since prior surgery * Concurrent surgery for local recurrence allowed if patient remains disease free